Related Experiment Video

Updated: May 8, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

[Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications]

Aneta Grabarska1, Magdalena Dmoszyńska-Graniczka, Ewa Nowosadzka

  • 1Katedra i Zakład Biochemii i Biologii Molekularnej Uniwersytetu Medycznego w Lublinie.

Postepy Higieny I Medycyny Doswiadczalnej (Online)
|September 11, 2013
PubMed

Insights

Histone deacetylase inhibitors (HDACis) show promise as anti-cancer drugs by altering gene expression and inducing cancer cell death. Clinical trials are evaluating these agents for hematologic malignancies and solid tumors.

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Oncology

Background:

  • Histone deacetylases (HDACs) are key epigenetic regulators implicated in cancer.
  • HDAC inhibitors (HDIs) are investigated as novel anti-cancer therapeutics.
  • HDIs induce histone hyperacetylation, altering gene expression and chromatin structure.

Purpose of the Study:

  • To review the molecular mechanisms of HDI action in cancer cells.
  • To summarize clinical trials of promising HDIs for cancer treatment.

Main Methods:

  • Review of molecular mechanisms of HDAC inhibition.
  • Summary of clinical trial data for HDIs in hematologic malignancies and solid tumors.

Main Results:

  • HDIs modulate chromatin structure, affecting numerous genes and pathways.
  • HDIs inhibit cell cycle progression, angiogenesis, and induce apoptosis.
  • Several HDIs show promising anti-cancer effects in clinical trials, used alone or in combination therapy.

Conclusions:

  • HDIs represent a promising class of anti-cancer drugs with diverse mechanisms of action.
  • Ongoing clinical trials are evaluating the efficacy of various HDIs in treating hematologic malignancies and solid tumors.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

Related Concept Videos

Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...